EUCTR2004-001667-22-IT进行中（未招募）不适用
Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck (''EXTREME'')
MERCK S.P.A.0 个研究点开始时间: 2004年12月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMERecurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 7.0Level: LLTClassification code 10025960EUCTR2004-001667-22-CZMerck KGaA420
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMEMedDRA version: 7.0Level: LLTClassification code 10025960Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)EUCTR2004-001667-22-SEMerck KGaA420
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMEEUCTR2004-001667-22-GBMerck KGaA420
进行中（未招募）
1 期
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMERecurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 7.0Level: LLTClassification code 10025960EUCTR2004-001667-22-SKMerck KGaA420
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMERecurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 7.0Level: LLTClassification code 10025960EUCTR2004-001667-22-HUMerck KGaA420